By Sriparna Roy and Sahil Pandey April 16 (Reuters) - Eli Lilly said on Thursday its newly approved obesity pill was not ...

"Lilly debuts more Foundayo data as FDA requests post-marketing trials" was originally created and published by ...

Lilly plans to file Foundayo with the FDA for type 2 diabetes by end of Q2 after the ACHIEVE-4 trial met its primary ...

Eli Lilly is wasting no time in pursuit of the next indication for its newly christened obesity pill Foundayo, presenting new ...

Right after the FDA flagged safety concerns for Eli Lilly’s newly approved obesity pill, the pharma posted diabetes data ...

Regulators have asked Eli Lilly to conduct additional trials for its weight-loss pill, Foundayo.

Even as Eli Lilly gets underway with its next major obesity launch in Foundayo, an FDA document related to the oral treatment ...

April 16 () - Eli Lilly said on Thursday its newly approved obesity ‌pill helped reduce the risk ‌of major cardiovascular ...

Eli Lilly says it has the safety data it needs to shore up the recent speedy approval of its oral obesity therapy Foundayo, ...

The FDA also asked Lilly to conduct a milk-only lactation study in women who have received a dose to assess concentrations of ...

FDA required additional post-approval evaluation of myocardial infarction, stroke, and other cardiovascular events because ...

The U.S. Food and Drug Administration is asking Eli Lilly and Company, the leading manufacturer of GLP-1s, for additional ...